AnaCardio AC01 — Ghrelin Receptor Agonist in HFrEF
Heart Failure with Reduced Ejection Fraction (HFrEF)
About this study
Phase 2B study of AC01, an oral ghrelin receptor agonist, administered over 12 weeks in patients with chronic advanced heart failure with reduced ejection fraction (HFrEF). The trial is in site start-up.
Sponsor: AnaCardio AB · Principal Investigator: Pedro Martinez-Clark, MD, FACC
Key eligibility
- Adults with chronic advanced HFrEF
- On stable guideline-directed medical therapy
- Meeting protocol functional and biomarker criteria
Eligibility above is a summary. Final qualification is determined by the study protocol and a screening visit with our team.
What participation involves
Most studies follow the same general flow: a phone pre-screen, an in-person screening visit, informed consent, baseline testing, the treatment phase, and follow-up visits. Study-related care is provided at no cost. You may withdraw at any time, for any reason.
Note
This page is a plain-language overview. For the official, definitive protocol summary, please refer to ClinicalTrials.gov or speak with our coordinator.